Xilio Therapeutics Inc XLO 深 滬
已收盤 05-08 16:00:00 美东时间
7.74
-0.070
-0.90%
華盛通- 最 高7.91
- 今 開7.75
- 成交量 2.29万股
- 最 低 7.60
- 昨 收 7.81
- 總市值 4630.72万
- 52周最高 16.10
- 市盈率 靜 --
- 換手率 0.38%
- 52周最低 6.4652
- 委 比 50.70%
- 總股本 598.28万
- 歷史最高 391.30
- 量 比 0.59
- 振 幅 3.97%
- 歷史最低 6.4652
- 每 手 1
- 風險率 1.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Xilio's XTX601 Shows Tumor-Selective Activation And Strong Preclinical Anti-Tumor Activity With Favorable Safety Profile At AACR 2026
XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models Consistent with Xilio's clinically-validated masking technology, XTX601 was well
04-18 04:02
Xilio Therapeutics names Cheryl Blanchard to board of directors
Xilio Therapeutics names Cheryl Blanchard to board of directors Xilio Therapeutics appointed Cheryl R. Blanchard to board of directors. Blanchard is executive chair at Anika Therapeutics; previously served as its president and CEO. Her prior roles include president and CEO of Microchips Biotech thro
04-16 19:35
BUZZ-U.S. STOCKS ON THE MOVE-Energy firms, Cencora, Stryker
BUZZ-U.S. STOCKS ON THE MOVE-Energy firms, Cencora, Stryker Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 20 (Reuters) - The main U.S. indexes were on track to open highe
03-23 21:08
Xilio Therapeutics Q4 EPS $0.81 Beats $(0.12) Estimate, Sales $13.686M Beat $7.960M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $(0.12) by 775 percent. This is a 128.93 percent increase over losses of $(2.80) per share from
03-23 19:47
Xilio Therapeutics posts Q4 profit on higher collaboration revenue
Xilio Therapeutics posts Q4 profit on higher collaboration revenue Overview US biotechnology firm's Q4 net income turned positive, driven by higher collaboration and license revenue Operating expenses for Q4 increased year-over-year due to expanded R&D and clinical activities Company extended cash r
03-23 19:38
Why Playboy Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Playboy (PLBY) shares rise in pre-market trading after reporting better-than-expected Q4 results. Other gainers include PTOR, LNAI, LIDR, ISPC, WNW, JVA, NUAI, XLO, and BW. Losers include PRSO, DFLI, LNSR, and MVST.
03-18 00:19
Xilio Therapeutics Announces 1-For-14 Reverse Stock Split, Effective March 13
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that it will implement a 1-for-14
03-12 20:32
BRIEF-Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BRIEF-Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) March 2 (Reuters) - Xilio Therapeutics Inc XLO.O : XILIO THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text: ID:nGNXbb2cqs Further company coverage: XLO.O (( Reuters.Brief
03-02 20:33
Xilio Therapeutics Grants Inducement Stock Options to New Employees
Xilio Therapeutics Grants Inducement Stock Options to New Employees Xilio Therapeutics granted non-qualified stock options covering 50,050 shares to two new employees under its 2022 Inducement Stock Incentive Plan, effective March 1, 2026. The options have a $0.5283 per-share exercise price, a 10-ye
03-02 20:30
Xilio Therapeutics Inc. Held a Special Stockholder Meeting
Xilio Therapeutics Inc. Held a Special Stockholder Meeting Xilio Therapeutics, Inc. held a special meeting of stockholders on February 23, 2026. Stockholders approved an amendment to the restated certificate of incorporation to authorize a reverse stock split within a specified range, with the final
02-24 20:31
